February 21, 2019

Douglas Godshall
President & Chief Executive Officer
ShockWave Medical, Inc.
5403 Betsy Ross Drive
Santa Clara, California 95054

       Re: ShockWave Medical, Inc.
           Registration Statement on Form S-1
           Filed February 8, 2019
           File No. 333-229590

Dear Mr. Godshall:

       We have reviewed your registration statement and have the following
comments. In
some of our comments, we may ask you to provide us with information so we may
better
understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments. Unless
we note
otherwise, our references to prior comments are to comments in our February 1,
2019 letter.

Form S-1 Filed on February 8, 2019

Dilution, page 79

1.     Please expand your revisions in response to prior comment 6 to address
the "total
       consideration" and "average price per share" columns of the table on
page 80.
Critical Accounting Policies and Estimates
Stock-based Compensation, page 94

2.     Please revise your filing to explain in more detail the methodologies
and underlying
       assumptions that your board of directors utilized in determining the
fair value of your
       common stock underlying your equity instruments granted during the
periods presented.
       Additionally, provide us with the underlying common stock share price of
the equity
 Douglas Godshall
ShockWave Medical, Inc.
February 21, 2019
Page 2
      instruments issued and progressively bridge to the current estimated IPO
price the fair
      value per share determinations used for each option grant since January
1, 2018. We will
      delay our assessment of your response pending inclusion of the estimated
IPO price in the
      filing.
Director Independence, page 141

3.    Your revisions in this section imply that less than a majority of your
board of directors is
      independent. If that is correct, please expand to clarify how you will
comply with
      exchange listing rules following completion of this offering.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Tara Harkins at 202-551-3639 or Lynn Dicker, Senior
Accountant, at
202-551-3616 if you have questions regarding comments on the financial
statements and related
matters. Please contact Thomas Jones at 202-551-3602 or Geoff Kruczek, Special
Counsel, at
202-551-3641 with any other questions.



                                                             Sincerely,
FirstName LastNameDouglas Godshall
                                                             Division of
Corporation Finance
Comapany NameShockWave Medical, Inc.
                                                             Office of
Electronics and Machinery
February 21, 2019 Page 2
cc:       Alan Denenberg
FirstName LastName